In this regard, revumenib has demonstrated encouraging safety and efficacy when studied in AML patients with a rearrangement of KMT2A or mutation of nucleophosmin 1 (NPM1) [21]. The gene discussed is NPM1; the disease is acute myeloid leukemia.